NEW YORK, Jan. 2, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq: NBS ) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple upcoming conferences in January.
ECI's Scale-Up and Manufacturing of Cell-Based Therapies III
- Date and Time: Tuesday, January 7, 2014, 3:05 PM PST
- Venue: Hyatt Regency, San Diego, California
- Session: Engineering a process for commercial success – strategic considerations and technology alternatives
- Speaker: Brian Hampson, MS, Senior Director, Engineering & Innovation of PCT
Biotech Showcase 2014
- Date and Time: Monday, January 13, 2014, 11:30 AM PST
- Venue: Parc 55 Wyndham San Francisco – Union Square, San Francisco, California
- Session: Company Presentation
- Speaker: Robert A. Preti, PhD, President of PCT, Chief Scientific Officer of NeoStem
7 th Annual OneMedForum
- Venue: The Westin San Francisco Market Street, San Francisco, California
- Presentation Topics: Company Presentations
- Presentation #1 Date and Time: Monday, January 13, 2014, 11:50 AM PST
- Presentation #1 Speaker: Robin L. Smith, MD, MBA, Chairman and CEO of NeoStem
- Presentation #2 Date and Time: Tuesday, January 14, 2014, 9:50 AM PST
- Presentation #2 Speaker: Andrew L. Pecora, MD, FACP, Chief Visionary Officer of NeoStem
Alliance for Regenerative Medicine's 4 th Annual State of the Industry Briefing
- Date and Time: Monday, January 13, 2014, 8:00 AM PST
- Venue: Parc 55 Wyndham San Francisco – Union Square, San Francisco, California
- Session: Key Clinical Data Inflection Points for 2014 Panel
- Panelist: Andrew L. Pecora, MD, FAHA, Chief Visionary Officer of NeoStem
Noble Financial Capital Markets Tenth Annual Equity Conference
- Date and Time: Monday, January 20, 2014 at 10:00 AM EST
- Venue: Club Med Sandpiper Bay, Sandpiper Bay, Florida
- Session: Company Presentation
- Moderator: Robin L. Smith, MD, MBA, Chairman and CEO of NeoStem
Ninth International Conference on Cell Therapy for Cardiovascular Disease
- Venue: Vivian and Seymour Milstein Family Heart Center, New York, New York
- Session #1 Date and Time: Thursday, January 23, 2014, 9:28 AM EST
- Session #1: AMR-001 and PreSERVE Study: Autologous CD34+ Cells for AMI
- Session #1 Speaker: Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development of NeoStem
- Session #2 Date and Time: Friday, January 24, 2014, 10:30 AM EST
- Session #2: Clinical Science and Pivotal Studies: Durable Partnerships in Regenerative Medicine
- Session #2 Discussant: Douglas W. Losordo, MD, FACC, FAHA, Chief Medical Officer of NeoStem
About NeoStem, Inc.
NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
For more information, please visit www.neostem.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the successful development of cellular therapies, including with respect to AMR-001 and regulatory T cells, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
Investor Contact: LifeSci Advisors, LLC Michael Rice Founding Partner Phone: +1-646-597-6979 Email: Media Contact: NeoStem, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email:
